Validation of Driving Simulator to Blood Alcohol Concentration Standards for Impaired Driving (ALCDrive)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00559819
Recruitment Status : Active, not recruiting
First Posted : November 16, 2007
Last Update Posted : September 27, 2017
Information provided by (Responsible Party):
Mario Moric, Rush University Medical Center

Brief Summary:
The proposed study will validate and determine sensitivity of our new driving simulator, created to evaluate driving ability in a related study to show similar driving performance between patients on chronic opioid treatment and a control group. Although the commercial version of the simulator has been validated for certain populations and certain measures, these require re-calibration for our own clinical study. The investigators propose a prospective randomized clinical trial to evaluate driving skills under alcohol consumption using a driving simulator. Two groups of study subjects will be utilized, with the majority (80%) receiving alcohol and placebo at different times. A smaller set of study subjects (20%) will be given placebo on both trials to evaluate learning effects and placebo blinding effectiveness. Each group will take the driving test at three time points: once as a baseline at the beginning of the study, once after the 1st dosing of the placebo and again after dosing two of the alcohol or placebo beverage. This information will allow us to evaluate driving ability under other potentially impairing conditions such as opioid usage.

Condition or disease Intervention/treatment Phase
Driving Intoxication Impairment Alcohol Impaired Driving Drug: placebo Drug: Alcohol Phase 3

Detailed Description:

Subjects will be recruited via discreet flyers distributed around the Rush University Medical Campus. Subjects will be scheduled so that a maximum of 6 participants are evaluated on the same day. Some evaluation days may fall on the weekend. Study duration is estimated at 4-5 hours, and at the completion the subjects will be driven to their respective residences.

Upon arrival subjects will complete questionnaires which contain demographic information and measures to evaluate possible alcohol abuse issues. All subjects will be given a short driving simulator practice and then the baseline simulator trial. Subjects will be randomized into two groups as part of a study, with an 80% probability of selection for group A and a 20% probability of selection for Group P. Group P will only be given placebos so that any learning effects can be estimated. In addition to the baseline, both groups will take the full driving test two additional times each preceded by an alcohol or placebo dosing. Of these two trials only on Trial#2 of Group A is alcohol given. Both groups will receiver placebo on simulator Trial #1.

Alcohol trial (Group A only):

The alcohol dose will consist of a 40% alcohol (vodka) liquor in a beverage containing 2 parts orange juice and 1 part liquor. The exact amount/volume of alcohol will be determined based on factors such as weight and sex so as to reach a peak BAC of 0.08%.

The primary contrast of interest is the comparison between the placebo and the alcohol dosed driving simulation trials. Analyses will take place with general linear models framework, using "Proc Mixed" to model the repeated measures design and produce accurate estimate of the pre-planned comparisons as well as main effects and longitudinal estimates. Various outcome variables that measure driving ability will be used, the three primary measures being: a measure of weaving (Standard Deviation of Lateral Deviation), Reaction Time (RT) to unexpected stimuli, and number of accidents. The placebo, Group P, will be evaluated to estimate the effect of learning and to estimate the effectiveness of the placebo sham.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose: Diagnostic
Official Title: Validation of Driving Simulator Measures and Calibration to Blood Alcohol Concentration Standards for Impaired Driving
Study Start Date : February 2008
Estimated Primary Completion Date : July 2018
Estimated Study Completion Date : December 2018

Arm Intervention/treatment
Active Comparator: Alcohol
Drug: Alcohol
Dose with Alcohol (Vodka) to make blood alcohol concentration 0.08%
Other Name: Vodka

Placebo Comparator: Placebo
Orange juice
Drug: placebo
Placebo (orange juice), same volume as alcohol
Other Name: Orange Juice

Primary Outcome Measures :
  1. Weaving (Standard Deviation of Lateral Deviation) [ Time Frame: 6 h ]

Secondary Outcome Measures :
  1. Reaction Time (RT) to unexpected stimuli, and number of accidents [ Time Frame: 6 h ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   21 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Legal drinking age (=> 21).
  2. Moderate alcohol consumption

    • Defined as: at least 1 unit per week but less than 20 units per week. (unit = 12 oz. beer or equivalent).
  3. Current driver's license.
  4. Subjects can understand and communicate in English.

Exclusion Criteria:

  1. Known alcoholic or drug abuser.
  2. Alcohol naïve.
  3. Use of medications that may be aggravated (or contraindicated) by alcohol.
  4. Pregnant or breast feeding.
  5. Younger than 21 years or older than 80 years.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00559819

United States, Illinois
Rush University Medical Center
Chicago, Illinois, United States, 60612
Sponsors and Collaborators
Rush University Medical Center
Study Director: Asokumar Buvanendran, MD Rush University Medical Center

Responsible Party: Mario Moric, Research Coordinator, Rush University Medical Center Identifier: NCT00559819     History of Changes
Other Study ID Numbers: MMoric111207
First Posted: November 16, 2007    Key Record Dates
Last Update Posted: September 27, 2017
Last Verified: September 2017

Keywords provided by Mario Moric, Rush University Medical Center:

Additional relevant MeSH terms:
Anti-Infective Agents, Local
Anti-Infective Agents
Central Nervous System Depressants
Physiological Effects of Drugs